ADT
Androgen deprivation therapy. LHRH agonists, antagonists, or orchiectomy. In BAT it stays on so the only testosterone is the injected pulse.
Language
A short glossary so the papers do not bounce.
Androgen receptor (AR)
The protein cells use to read testosterone and DHT. CRPC cells often overexpress it — the liability BAT tries to exploit.
ARPI / ARSI
Enzalutamide, apalutamide, darolutamide, abiraterone. BAT is often used after one fails, and sometimes to resensitize to the next.
AR-V7
Splice variant missing the ligand-binding domain. Marker studied in BAT trials, not a standalone rule-out.
BAT
Rapid cycling between supraphysiologic and near-castrate testosterone, usually 400 mg cypionate IM every 28 days on ADT. “Bipolar” names the poles, not bipolar disorder.
aBAT
Adaptive BAT: cycle length, pulse width, and partners change with ecosystem type instead of a fixed 28-day CRPC calendar.
Castrate
Usually T <50 ng/dL (some labs <20). BAT troughs are often 100–200 ng/dL just before the next shot.
CRPC / mCRPC
Disease that grows despite castrate testosterone. Setting with the most BAT evidence.
HSPC / mHSPC
Disease that still responds to testosterone suppression. BAT here is experimental (BATMAN, SPIDERMAN).
Hematocrit
Red-cell fraction. Testosterone can raise it. A standard reason to pause.
PARP inhibitor
Olaparib and kin. Combined with BAT in phase II because SPA can induce DNA damage.
PCWG3
Rules for reading bone scans. Needed because BAT can flare a scan without true progression.
PSA / PSA50
Androgen-driven protein. A bump on BAT is not automatic failure. PSA50 is a ≥50% drop — convenient, not the same as living longer.
Resensitization
After BAT, a previously failing ARPI often works again. TRANSFORMER’s 77.8% crossover PSA50 is the quoted number.
SPA / SPT
Supraphysiologic androgen / testosterone. The high pole, typically 1,000–3,000 ng/dL after injection.
Testosterone cypionate
Long-acting IM ester. Standard Hopkins BAT dose 400 mg gluteal every 28 days. Off-label for prostate cancer.